These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 27339590)

  • 1. Update to South Asian consensus guideline: Use of newer insulins in diabetes during Ramadan Revised Guidelines on the use of insulin in Ramadan.
    Pathan F; Latif ZA; Sahay RK; Zargar AH; Raza SA; Khan AK; Siddiqui NI; Amin F; Ishtiaq O; Shrestha D; Somasundaram N; Kalra S
    J Pak Med Assoc; 2016 Jun; 66(6):777-8. PubMed ID: 27339590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. South Asian consensus guideline: Use of GLP-1 receptor agonists during Ramadan: Update 2016 Revised Guidelines on the use of GLP-1A in Ramadan.
    Pathan F; Latif ZA; Sahay RK; Zargar AH; Raza SA; Khan A; Siddiqui NI; Amin F; Somasundaram N; Shrestha D; Kalra S
    J Pak Med Assoc; 2016 Jun; 66(6):774-6. PubMed ID: 27339589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Original paper: Efficacy and safety analysis of insulin degludec/insulin aspart compared with biphasic insulin aspart 30: A phase 3, multicentre, international, open-label, randomised, treat-to-target trial in patients with type 2 diabetes fasting during Ramadan.
    Hassanein M; Echtay AS; Malek R; Omar M; Shaikh SS; Ekelund M; Kaplan K; Kamaruddin NA
    Diabetes Res Clin Pract; 2018 Jan; 135():218-226. PubMed ID: 29183844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
    Kaneko S; Chow F; Choi DS; Taneda S; Hirao K; Park Y; Andersen TH; Gall MA; Christiansen JS;
    Diabetes Res Clin Pract; 2015 Jan; 107(1):139-47. PubMed ID: 25498130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk stratification of persons on premixed insulin in Ramadan.
    Kalra S; Jawad F; Latif ZA; Pathan MF
    J Pak Med Assoc; 2017 Nov; 67(11):1771-1774. PubMed ID: 29171581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects.
    Haahr H; Sasaki T; Bardtrum L; Ikushima I
    J Diabetes Investig; 2016 Jul; 7(4):574-80. PubMed ID: 27181070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes.
    Franek E; Haluzík M; Canecki Varžić S; Sargin M; Macura S; Zacho J; Christiansen JS
    Diabet Med; 2016 Apr; 33(4):497-505. PubMed ID: 26435365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 twice daily in insulin-experienced Japanese subjects with uncontrolled type 2 diabetes: Subgroup analysis of a Pan-Asian, treat-to-target Phase 3 Trial.
    Taneda S; Hyllested-Winge J; Gall MA; Kaneko S; Hirao K
    J Diabetes; 2017 Mar; 9(3):243-247. PubMed ID: 27059529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of insulin degludec (IDeg)/insulin Aspart (IAsp) co-formulation therapy twice-daily with free combination of GLP-1 receptor agonist liraglutide plus insulin degludec in Tochigi: IDEAL Trial.
    Aso Y; Takada Y; Tomotsune K; Chiba Y; Matsumura M; Jojima T; Sato M; Fujita N; Kuroda H; Murano S; Usui I
    Int J Clin Pract; 2021 Apr; 75(4):e13734. PubMed ID: 33099848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes.
    Christiansen JS; Niskanen L; Rasmussen S; Johansen T; Fulcher G
    J Diabetes; 2016 Sep; 8(5):720-8. PubMed ID: 26612062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes.
    Haluzík M; Fulcher G; Pieber TR; Bardtrum L; Tutkunkardas D; Rodbard HW
    Diabetes Obes Metab; 2018 Jul; 20(7):1585-1592. PubMed ID: 29451706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns.
    Demir T; Turan S; Unluhizarci K; Topaloglu O; Tukek T; Gogas Yavuz D
    Front Endocrinol (Lausanne); 2021; 12():616514. PubMed ID: 33776914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial.
    Yang W; Ma J; Hong T; Liu M; Miao H; Peng Y; Wang C; Xu X; Yang T; Nielsen AM; Pan L; Liu W; Zhao W
    Diabetes Obes Metab; 2019 Jul; 21(7):1652-1660. PubMed ID: 30869183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp).
    Kalra S; Atkin S; Cervera A; Das AK; Demir O; Demir T; Fariduddin M; Vo KT; Ku BJ; Kumar A; Latif ZA; Malek R; Matawaran BJ; Mehta R; Tran NQ; Panelo A; Ruder S; Saldana JR; Shaikh KA; Shakya A; Shrestha D; Unnikrishnan AG
    Adv Ther; 2018 Jul; 35(7):928-936. PubMed ID: 29796928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial.
    Niskanen L; Leiter LA; Franek E; Weng J; Damci T; Muñoz-Torres M; Donnet JP; Endahl L; Skjøth TV; Vaag A
    Eur J Endocrinol; 2012 Aug; 167(2):287-94. PubMed ID: 22660026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of analog insulin mix 50:50 with human insulin mix 30:70 in persons with type 2 diabetes during Ramadan.
    Hajjaji IM; Eshwihdi N; Barrowman N
    Int J Clin Pract; 2019 Jun; 73(6):e13348. PubMed ID: 30912213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of Clinical Trial Program and Applicability of Insulin Degludec/Insulin Aspart in Diabetes Management.
    Bantwal G; Wangnoo SK; Shunmugavelu M; Nallaperumal S; Harsha KP; Bhattacharyya A
    J Assoc Physicians India; 2015 May; 63(5 Suppl):21-8. PubMed ID: 26548031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience.
    Kalra S
    Indian J Endocrinol Metab; 2016; 20(4):564-7. PubMed ID: 27366727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes: A Real-World, Prospective, Non-interventional Study Across Six Countries.
    Fulcher GR; Akhtar S; Al-Jaser SJ; Medina J; Mohamed M; Nicodemus NA; Olsen AH; Singh KP; Kok A
    Adv Ther; 2022 Aug; 39(8):3735-3748. PubMed ID: 35752730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial.
    Fulcher GR; Christiansen JS; Bantwal G; Polaszewska-Muszynska M; Mersebach H; Andersen TH; Niskanen LK;
    Diabetes Care; 2014 Aug; 37(8):2084-90. PubMed ID: 24812432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.